Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $41.20.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $17.40, for a total value of $116,005.80. Following the completion of the transaction, the chief operating officer directly owned 269,974 shares of the company’s stock, valued at approximately $4,697,547.60. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $21.33, for a total transaction of $266,625.00. Following the sale, the chief executive officer owned 902,892 shares of the company’s stock, valued at approximately $19,258,686.36. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 99,984 shares of company stock worth $2,021,749 in the last ninety days. Corporate insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Several large investors have recently bought and sold shares of ELVN. Quantbot Technologies LP purchased a new position in shares of Enliven Therapeutics in the first quarter valued at $60,000. BNP Paribas Financial Markets grew its stake in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. AlphaQuest LLC purchased a new position in Enliven Therapeutics during the 3rd quarter valued at about $96,000. Tower Research Capital LLC TRC raised its position in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after acquiring an additional 3,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS lifted its holdings in shares of Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Price Performance

ELVN opened at $20.30 on Thursday. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $27.59. The stock has a market capitalization of $1.20 billion, a P/E ratio of -10.15 and a beta of 0.80. The business has a 50 day simple moving average of $20.19 and a 200-day simple moving average of $20.04.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Research analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.